What does the evidence say about Prebiotics Constipation Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Prebiotics Constipation Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. [Šuran Jelena (2026); evidence level 3] - Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. [Šuran Jelena (2026); evidence level 3] - Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. [Šuran Jelena (2026); evidence level 3] - It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. [Šuran Jelena (2026); evidence level 3] - Designed as a narrative review employing systematic search strategies to ensure comprehensive coverage while accommodating evidence heterogeneity, this study evaluates the efficacy and safety of probiotics, prebiotics, and synbiotics (PP/S) in FC with comorbid depression. [Dai Q (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.